A list of changes in the level of risk of products reviewed in e-lactancia during the last 3 months is shown. Tap the name of a product to access to its full information.

Daclizumab

Level of risk reviewed on 09/02/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Aflibercept, Ophtalmic use

Level of risk reviewed on 07/02/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

Dimethyl Fumarate

Level of risk reviewed on 31/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

COVID-19 vaccine

Level of risk reviewed on 29/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

Colchicine

Level of risk reviewed on 28/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

Flunitrazepam

Level of risk reviewed on 18/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

Clotiazepam

Level of risk reviewed on 18/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

Clonazepam

Level of risk reviewed on 18/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

Brotizolam

Level of risk reviewed on 18/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

Obinutuzumab

Level of risk reviewed on 13/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Nivolumab

Level of risk reviewed on 13/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Ustekinumab

Level of risk reviewed on 09/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

Iodine (as Thyroid Drug: Miligrams)

Level of risk reviewed on 08/01/2021

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Barberry

Level of risk reviewed on 23/12/2020

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Hydrastis

Level of risk reviewed on 21/12/2020

Increased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to High Risk.

Lovastatin

Level of risk reviewed on 17/12/2020

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Simvastatin

Level of risk reviewed on 17/12/2020

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Atorvastatin Calcium

Level of risk reviewed on 17/12/2020

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Trastuzumab

Level of risk reviewed on 17/12/2020

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Rosuvastatin Calcium

Level of risk reviewed on 16/12/2020

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.